Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation (IL-7tran)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01414660
Recruitment Status : Completed
First Posted : August 11, 2011
Last Update Posted : June 7, 2018
Information provided by (Responsible Party):
University Hospital, Lille

Brief Summary:
Three different white adipose tissue-related disorders, whether due to its excess (obesity), absence (lipoatrophies) or aberrant distribution (lipodystrophies), are paradoxically able to induce metabolic insulin resistance syndrome. The respective roles played by quantitative and qualitative anomalies of adipose tissue, gluco- and lipo-toxicity, liver and muscle insulin resistance, low-grade fat inflammation and immune alterations are not yet perfectly understood. In contrast to most organ transplantations that are often complicated by post-transplantation diabetes, diabetes cell therapy is associated with body weight loss, which is possibly related to the antiadipogenic effects of mTOR inhibitors (rapamycin or sirolimus). The aim of this study is thus to determine and monitor blood interleukin-7 and other cytokine levels; metabolic parameters; and fat mass distribution with DEXA and RMN, before and after a immunosuppressive regimen in patients receiving different kinds of transplantation (liver, kidney or islets) with normal weight and no type 2 diabetes before transplantation. In these patients, blood samples will be taken before and after transplantation, as will adipose tissue during the transplantation surgery, in order to constitute a plasma serum, gene and tissue bank for improving our knowledge of disorders linking fat mass, insulin resistance and immunity, especially post-transplantation diabetes.

Condition or disease Intervention/treatment
Immunodeficiency Secondary to Organ Transplantation Procedure: transplantation

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 49 participants
Observational Model: Case-Only
Time Perspective: Other
Official Title: Adipocytes, Insulin Resistance and Immunity: Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation
Actual Study Start Date : June 9, 2010
Actual Primary Completion Date : February 2018
Actual Study Completion Date : February 2018

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
type 1 diabetic patients undergoing islet transplantation
Procedure: transplantation
transplantation of islet, kidney or liver

non diabetic patients undergoing a liver transplantation
Procedure: transplantation
transplantation of islet, kidney or liver

non diabetic patients undergoing a kidney transplantation
Procedure: transplantation
transplantation of islet, kidney or liver

Primary Outcome Measures :
  1. interleukin 7 [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Interleukin 2 [ Time Frame: 1 year ]
  2. Interleukin 4 [ Time Frame: 1 year ]
  3. Interleukin 9 [ Time Frame: 1 year ]
  4. Interleukin 15 [ Time Frame: 1year ]
  5. Interleukin 21 [ Time Frame: 1year ]
  6. TNFa [ Time Frame: 1 year ]
  7. Interleukin 1b [ Time Frame: 1 year ]
  8. Interleukin 6 [ Time Frame: 1year ]
  9. Interleukin 8 [ Time Frame: 1 year ]
  10. Interleukin 10 [ Time Frame: 1 year ]
  11. Interleukin 18 [ Time Frame: 1 year ]
  12. leptin [ Time Frame: 1 year ]
  13. adiponectin [ Time Frame: 1 year ]
  14. Blood cells of innate and adaptative immunity analysis [ Time Frame: 1 year ]
  15. fat mass [ Time Frame: 1 year ]
  16. metabolic parameters [ Time Frame: 1 years ]

Biospecimen Retention:   Samples With DNA
wholeblood and tissue bank

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing a transplantation in Endocrinology Metabolism department, Nephrology department and Liver Transplantation department in Lille University Hospital, Amiens University Hospital, Caen University Hospital, Rouen University Hospital and Reims University Hospital.

Inclusion Criteria:

  • Male and Female
  • More than 18 years old
  • BMI inferior to 30 kg/m2
  • non diabetic patients who need a kidney or a liver transplantation(Glucose blood level <1,26 g/L without any antidiabetic drug)
  • OR included in the islet transplantation protocol because of a C peptide negative brittle or difficult to treat diabetes.
  • cover under the social security

Exclusion Criteria:

  • Unable to receive enlightened information
  • Refusal to sign the consent
  • Auto immune disease (kidney, liver or chronic inflammatory disease)
  • need for a kidney-pancreas transplantation
  • Creatinin > 15 mg / L for patients non concerned by kidney transplantation
  • Sepsis
  • Oestrogens, raloxifene
  • Active alcohol Intoxication
  • Cancers or autoimmune diseases;
  • Psychiatric Pathology
  • Active infection including hepatitis C or HIV;
  • Age under 18 years or above 65 years
  • Participation in another study excluded the possibility of participating in another protocol
  • No cover under the social security
  • Pregnant or lactating women
  • patients under guardianship, persons deprived of liberty

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01414660

Amiens University Hospital
Amiens, France
Caen University Hospital
Caen, France
Lille University Hospital
Lille, France
Reims University Hospital
Reims, France
Rouen University Hospital
Rouen, France
Sponsors and Collaborators
University Hospital, Lille
Principal Investigator: Marie-Christine VANTYGHEM, MD, PhD Lille University Hospital

Responsible Party: University Hospital, Lille Identifier: NCT01414660     History of Changes
Other Study ID Numbers: 2009_09/0940
2009-A01169-48 ( Other Identifier: ID-RCB number, ANSM )
B91413-80 ( Other Identifier: AFSSAPS )
PHRC 2009/API ( Other Identifier: DHOS )
First Posted: August 11, 2011    Key Record Dates
Last Update Posted: June 7, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University Hospital, Lille:
interleukin 7

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Immune System Diseases